Novo Nordisk objects to proposed reimbursement change for its fast-acting insulin in Denmark

Novo Nordisk does not concur with an assessment from the Danish Medicines Agency's Reimbursement Committee, which could result in the pharmaceutical company's fast-acting insulin Fiasp receiving conditional reimbursement instead of general reimbursement status.
Photo: Tidsvilde Stine/Ritzau Scanpix
Photo: Tidsvilde Stine/Ritzau Scanpix
by CHRISTOPHER DUE KARLSSON, translated by daniel pedersen

The Reimbursement Committee, which advises the the Danish Medicines Agency on drug reimbursements, has proposed a reassessment of the drug Fiasp, and the company behind the product, Novo Nordisk, has voiced its opposition to the change.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading